drug · small molecule
camizestrant
pre_registrationupdated 3mo agoby $AZN ASTRAZENECA PLC🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 5Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 3 investigational indications.
targets
Estrogen receptor
all catalysts(1)
fda advisory committee meeting · 1
Trials studying camizestrant
- phase3An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
- phase2Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
- phase3Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- phase3A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
- phase3A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- phase2A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
- phase2Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
- phase1A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants
News(8)
- ‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal everIf AstraZeneca and Bristol Myers Squibb were to successfully become one company, analysts say it could reset the current deal environment, which has picked up greatly in the first half of the year.biospace · 8d ago
- Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myelomaNovo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.biopharma_dive · 18d ago
- Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readoutsWith a Phase 3 failure denting the rare disease drug’s prospects, AstraZeneca has little room for error as it plots a path toward its ambitious 2030 sales target.biospace · 20d ago
- AstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as WavePlus news about Kailera, Alfasigma, Junshi and Kura. ⏰ FDA delays AstraZeneca’s camizestrant PDUFA date: The FDA has extended its PDUFA date for AstraZeneca’s breast cancer drug camizestrant, a few…endpoints · 2mo ago
- Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ASCO 2026.onclive · 3mo ago
- ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You GoBreast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.onclive · 3mo ago
- Summit’s ‘self-inflicted’ stumble; Esperion’s take-private dealSummit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast c…biopharma_dive · 3mo ago
- FDA's oncology advisors vote against 'new paradigm' in AstraZeneca trialIn its first meeting in about nine months, the FDA’s advisory committee of oncology experts voted 6-3 Thursday that a late-stage trial for AstraZeneca’s oral SERD camizestrant didn't show a “clinic…endpoints · 3mo ago
Data sources
last refreshed 26m ago
Found something off?
comments(0)
5-min edit window · permanent after that